Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CING NASDAQ:FNCH NASDAQ:KTTA NASDAQ:VYNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$5.17+7.5%$4.21$1.80▼$20.83$20.42M-0.791.10 million shs153,549 shsFNCHFinch Therapeutics Group$12.50$13.22$1.27▼$15.85$20.08M1.212,097 shs1,390 shsKTTAPasithea Therapeutics$0.72+4.2%$0.82$0.65▼$7.50$5.14M0.252.08 million shs76,321 shsVYNEVYNE Therapeutics$1.16-3.3%$1.16$0.85▼$4.30$18.25M1.78231,238 shs753,325 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate+1.91%+8.58%+8.09%+13.44%+1,298.26%FNCHFinch Therapeutics Group0.00%-1.96%-8.09%-3.85%+756.16%KTTAPasithea Therapeutics-1.38%+0.03%-13.52%-49.93%-88.52%VYNEVYNE Therapeutics-4.76%-13.04%+30.63%-35.14%-46.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCINGCingulate3.18 of 5 stars3.55.00.00.02.90.80.6FNCHFinch Therapeutics Group0.7891 of 5 stars0.05.00.00.00.01.70.6KTTAPasithea Therapeutics1.4396 of 5 stars0.05.00.00.02.21.70.6VYNEVYNE Therapeutics2.9445 of 5 stars3.53.00.00.03.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCINGCingulate 3.00Buy$26.00402.90% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/AKTTAPasithea Therapeutics 0.00N/AN/AN/AVYNEVYNE Therapeutics 3.00Buy$6.25438.79% UpsideCurrent Analyst Ratings BreakdownLatest KTTA, FNCH, VYNE, and CING Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $61.005/19/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $11.004/25/2025VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.75 ➝ $4.504/21/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $60.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCINGCingulateN/AN/AN/AN/A$2.32 per shareN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/AKTTAPasithea TherapeuticsN/AN/AN/AN/A$10.60 per shareN/AVYNEVYNE Therapeutics$500K35.29N/AN/A$3.53 per share0.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCINGCingulate-$15.55M-$8.480.00N/AN/AN/A-229.78%-142.28%8/12/2025 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/AKTTAPasithea Therapeutics-$13.90M-$10.600.00∞N/AN/A-88.14%-81.21%8/12/2025 (Estimated)VYNEVYNE Therapeutics-$39.83M-$0.990.00N/AN/A-6,974.55%-71.89%-58.94%8/13/2025 (Estimated)Latest KTTA, FNCH, VYNE, and CING EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025VYNEVYNE Therapeutics-$0.24N/AN/AN/A$0.15 millionN/A8/12/2025Q2 2025CINGCingulate-$0.82N/AN/AN/AN/AN/A5/15/2025Q1 2025KTTAPasithea TherapeuticsN/A-$1.61N/A-$1.61N/AN/A5/8/2025Q1 2025CINGCingulate-$1.00-$1.04-$0.04-$1.04N/AN/A5/8/2025Q1 2025VYNEVYNE Therapeutics-$0.29-$0.20+$0.09-$0.20$0.05 million$0.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCINGCingulateN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCINGCingulate0.161.871.87FNCHFinch Therapeutics GroupN/A3.873.87KTTAPasithea TherapeuticsN/A3.843.84VYNEVYNE TherapeuticsN/A4.474.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCINGCingulate41.31%FNCHFinch Therapeutics Group21.77%KTTAPasithea Therapeutics23.92%VYNEVYNE Therapeutics83.78%Insider OwnershipCompanyInsider OwnershipCINGCingulate5.27%FNCHFinch Therapeutics Group44.90%KTTAPasithea Therapeutics16.30%VYNEVYNE Therapeutics4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCINGCingulate204.25 million4.02 millionNot OptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataKTTAPasithea Therapeutics37.44 million6.23 millionNot OptionableVYNEVYNE Therapeutics3015.21 million14.48 millionNot OptionableKTTA, FNCH, VYNE, and CING HeadlinesRecent News About These CompaniesVYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline ProgressJuly 11, 2025 | insidermonkey.comVYNE Therapeutics (NASDAQ:VYNE) Stock Price Down 9.5% - Should You Sell?July 8, 2025 | americanbankingnews.comVyne prunes psoriasis trial under FDA hold, but keeps faith in BET inhibitorJuly 2, 2025 | fiercebiotech.comFVYNE Therapeutics Provides Update on VYN202 Program Following FDA Clinical Hold for Psoriasis TrialJuly 2, 2025 | quiverquant.comQVYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202July 2, 2025 | globenewswire.comVYNE Stock Touches 52-Week Low at $0.96 Amid Market ChallengesMay 31, 2025 | investing.comVYNE Therapeutics First Quarter 2025 Earnings: Beats ExpectationsMay 12, 2025 | finance.yahoo.comVYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comVYNE Therapeutics' Psoriasis Drug Trial Halted By FDA Over Toxicity Concerns; Stock Down.April 27, 2025 | nasdaq.comVYNE Therapeutics Inc. Faces FDA Clinical Hold on VYN202 Phase 1b Trial for Plaque PsoriasisApril 27, 2025 | nasdaq.comAnalysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and VYNE Therapeutics (VYNE)April 26, 2025 | markets.businessinsider.comVYNE Therapeutics Inc.: VYNE Therapeutics Provides Update on VYN202 ProgramApril 25, 2025 | finanznachrichten.deVYNE shares tumble after FDA clinical hold on psoriasis drug studyApril 25, 2025 | za.investing.comVyne Crashes After Safety Signal in Dogs Puts Hold on Clinical Trial of Plaque PsoriasisApril 25, 2025 | biospace.comBFDA puts Vyne in a twist, slapping hold on psoriasis trial over testicular toxicity concernsApril 25, 2025 | fiercebiotech.comFFDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On HoldApril 25, 2025 | benzinga.comVYNE Therapeutics Provides Update on VYN202 ProgramApril 25, 2025 | globenewswire.comArtiva Biotherapeutics, Inc.: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical OfficerApril 9, 2025 | finanznachrichten.deArtiva Biotherapeutics Names New Chief Medical OfficerApril 8, 2025 | marketwatch.comVYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKTTA, FNCH, VYNE, and CING Company DescriptionsCingulate NASDAQ:CING$5.17 +0.36 (+7.48%) Closing price 04:00 PM EasternExtended Trading$5.18 +0.01 (+0.29%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Finch Therapeutics Group NASDAQ:FNCH$12.50 0.00 (0.00%) As of 01:37 PM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Pasithea Therapeutics NASDAQ:KTTA$0.72 +0.03 (+4.20%) Closing price 03:59 PM EasternExtended Trading$0.72 +0.00 (+0.28%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.VYNE Therapeutics NASDAQ:VYNE$1.16 -0.04 (-3.33%) Closing price 04:00 PM EasternExtended Trading$1.18 +0.03 (+2.16%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
